Federal Hemp Cliff — Public Law 119-37 Section 781 (Effective November 12, 2026)

Last verified: May 2026

What Public Law 119-37 Section 781 Does

Section 781 of the November 12, 2025 omnibus continuing-appropriations bill makes two structural changes to the federal definition of hemp:

• Total-THC standard. Hemp must be cannabis sativa with no more than 0.3% TOTAL THC (delta-9 plus 0.877 × THCA) by dry weight, replacing the 2018 Farm Bill’s delta-9-only standard.
• 0.4 mg per container cap. Finished hemp-derived cannabinoid products may contain no more than 0.4 mg total THC per container — a threshold far below typical 5–10 mg per gummy, 50–100 mg per beverage, or 500–1,000 mg per package configurations currently on the market.

The provisions take effect November 12, 2026 (one year after Trump’s signature, providing a transition window).

What This Closes

The federal cliff closes the two principal Farm Bill loopholes that have allowed hemp-derived intoxicants to flood Kansas (and U.S.) retail since 2018:

• The product-level dilution loophole. A 100-gram gummy with 10 mg of delta-9 THC = 0.0001% by weight, technically compliant with the 2018 Farm Bill 0.3%-by-weight standard. Under the 0.4 mg per container cap, the same gummy is illegal hemp.
• The THCA loophole. THCA flower at retail tests as compliant on Delta-9 alone but converts to Delta-9 THC when smoked. Under the new total-THC standard (delta-9 + 0.877 × THCA), THCA flower is illegal hemp.

The Industry Estimate

The U.S. Hemp Roundtable estimates the affected sector at approximately $28 billion in annual sales, supporting roughly 300,000 jobs and generating about $1.5 billion in state tax revenue. Industry analysis (Frier Levitt) describes the rule as rendering "the vast majority of hemp-derived cannabinoid products currently on the market federally unlawful."

Pending Federal Repeal/Extension

Multiple bills in Congress would repeal or delay the cliff:

• H.R. 6209 (American Hemp Protection Act of 2025) — Rep. Nancy Mace (R-SC). Would repeal the 0.4 mg per container cap and total-THC redefinition.
• H.R. 7010 — would push the effective date from November 12, 2026 to November 12, 2028.
• S. 3686 — Senate companion to H.R. 6209.

As of May 2026, none has cleared either chamber. The 2026 election cycle adds political uncertainty: the November 3, 2026 election will reshape the 2027 legislative calendar.

The Kansas Implications

For Kansas’s hemp gray market, the federal cliff is potentially decisive:

• If Section 781 takes effect November 12, 2026 without congressional repeal: Most current Kansas hemp-derived intoxicants become federally unlawful. Federal enforcement (DEA, U.S. Attorney for Kansas) becomes available. Kansas state-law enforcement (under K.S.A. § 21-5706 / § 65-4105) becomes substantially less contested because the products are no longer federally legal.
• If Congress repeals or extends: The Kansas hemp gray market continues operating in its current legal posture, with KBI / AG enforcement attempting state-level total-THC reinterpretation but facing federal-preemption challenges (as in the pending Indy Vapes lawsuit).

What Kansas Retailers Face in Late 2026

Kansas hemp retailers have a difficult choice in late 2026:

• Comply with the new federal definition — eliminating most product (0.4 mg per container cap eliminates virtually all dosed products).
• Wait for congressional repeal/delay — risking federal enforcement during the gap.
• Pivot to compliant low-dose products — THCA-free, delta-9-trace, CBD-dominant. The market segment is narrow.

The Trump Administration’s Mixed Signals

The Trump administration has sent contradictory signals on cannabis policy:

• April 23, 2026 federal Schedule III order (Acting AG Todd Blanche) — reclassifies state-licensed medical cannabis from Schedule I to Schedule III. Pro-legalization signal.
• November 12, 2025 PL 119-37 signature — tightens hemp framework. Anti-hemp-gray-market signal.

The two are not necessarily contradictory at the policy level (Schedule III for state-regulated cannabis; tighter hemp definition for federally-regulated hemp), but they signal different administrative priorities than a strictly prohibitionist or strictly legalizing administration would produce.

The Pharma/Nutraceutical Implications

Kansas’s biosciences corridor — anchored by KU Medical Center, the University of Kansas Cancer Center, and the bioscience cluster around Olathe — has produced a small but growing CBD pharmaceutical research community. Hill’s Pet Nutrition (Topeka, Colgate-Palmolive subsidiary) has explored hemp-derived ingredients in pet products. The federal cliff’s 0.4 mg cap would not affect zero-THC CBD pharmaceuticals (which are FDA-cleared in some applications) but would affect any hemp-derived consumer wellness product that includes meaningful cannabinoid content.

Related on this site: Kansas Delta-8 / THCA / HHC Gray Market, Kansas Industrial Hemp Program, Kansas Hemp-Shop Lawsuits.